Core Insights - The research published in "Nature Aging" reveals the critical role of the "lipid metabolism-microglial activation-neuroinflammation" axis in Alzheimer's disease, identifying MFE-2 as a novel therapeutic target for drug development [1][6] - CKBA, a small molecule candidate derived from traditional Chinese medicine, shows potential in treating Alzheimer's disease by effectively crossing the blood-brain barrier and exhibiting multiple therapeutic effects in animal models [1][2][6] Company Developments - The company is actively advancing the clinical development of CKBA for vitiligo (Phase III) and rosacea (Phase II/III), while accelerating the innovation drug development for Alzheimer's disease [2] - CKBA has demonstrated significant effects in improving cognitive function, reducing neuroinflammation, decreasing Aβ plaque burden, and alleviating anxiety behaviors in Alzheimer's disease model mice [1][6] Industry Context - Alzheimer's disease is the most common neurodegenerative disease globally, accounting for over half of dementia cases, characterized by progressive cognitive decline and persistent neuroinflammation [5] - The study addresses a critical scientific question regarding the mechanisms of lipid metabolism disruption and its role in immune activation in the brain, which has been underexplored [5][6]
泰恩康1.1类创新药CKBA治疗阿尔茨海默病的创新研究成果登上国际顶刊《Nature Aging》